SCHEMBL285934

SCHEMBL285934

CCCCc1nocc1C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
TSHR P16473 4/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
NOD2 Q9HC29 1/20 0.38
MAPK1 P28482 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22213880 0.86 TSHR (0.43) HSP90AA1TSHRSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL25526800 0.85 TSHR (0.42) HSP90AA1TSHRRAB9AALDH1A1MEN1
SCHEMBL22213850 0.85 TSHR (0.42) HSP90AA1TSHRALDH1A1MEN1KMT2A
SCHEMBL5275787 0.84 TSHR (0.47) HSP90AA1TSHRL3MBTL1ALDH1A1MEN1
SCHEMBL22439694 0.83 TSHR (0.46) HSP90AA1TSHRL3MBTL1ALDH1A1MEN1
SCHEMBL22213907 0.81 TSHR (0.44) HSP90AA1TSHRL3MBTL1ALDH1A1MEN1
SCHEMBL23985993 0.81 IDO1 (0.39) HSP90AA1TSHRALDH1A1MEN1KMT2A
SCHEMBL285678 0.81 GABRP (0.50) TSHRNFKB1TDP1L3MBTL1ALDH1A1
SCHEMBL11554506 0.80 TSHR (0.49) TSHRNPC1RAB9ANFKB1NFKB2
SCHEMBL25854777 0.80 TSHR (0.43) HSP90AA1TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427457-B1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS HOFFMANN LA ROCHE (CH) 2013-07-17 EP disclosed
US-8357703-B2 Pyridines HOFFMANN-LA ROCHE INC. (US) 2013-01-22 US disclosed
EP-2427457-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127978-A1 ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286117-A1 PYRIDINES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286117-A1 PYRIDINES GABRA5, GABRA1, GABRA4 HSP90AA1 4454/4885TSHR 411/4885NPC1 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.